Preparation, characterization, and evaluation of the co-amorphous systems of dasatinib to improve its pharmaceutical attributes

Abstract

Synthesizing co-amorphous systems is one of the most promising approaches to enhance the solubility and dissolution rate of pharmaceuticals as well as to improve their oral bioavailability. Herein, we screened eleven co-formers to form co-amorphous systems with an active pharmaceutical ingredient (API), dasatinib (DAS), to increase the drug's solubility and dissolution rate. The liquid-assisted grinding method was used to prepare the systems, and a series of techniques, including powder X-ray diffractometry (PXRD), solid-state nuclear magnetic resonance (SSNMR), differential scanning calorimetry (DSC), modulated DSC, and Fourier transform infrared spectroscopy-attenuated total reflectance (FTIR-ATR), was used for characterization. Formation of co-amorphous systems of DAS with malic acid (MAL) and succinic acid (SU) was confirmed. Solid-state NMR confirmed the presence of intermolecular H-bonding in DAS : SU, and its absence in the DAS : MAL system, which explained the recrystallization of the DAS : SU system within 30 days. Physical stability assessment under high humidity and temperature conditions led to enhanced re-crystallization of DAS : SU, while the DAS : MAL system retained its amorphous nature. Finally, the DAS : MAL co-amorphous system showed significant improvement in solubility and dissolution compared with crystalline DAS. These results show that the co-amorphous system of DAS : MAL exhibited enhanced solubility and dissolution compared with crystalline DAS and demonstrated stability under different conditions.

Graphical abstract: Preparation, characterization, and evaluation of the co-amorphous systems of dasatinib to improve its pharmaceutical attributes

Supplementary files

Article information

Article type
Paper
Submitted
16 Jan 2025
Accepted
24 Mar 2025
First published
25 Mar 2025

CrystEngComm, 2025, Advance Article

Preparation, characterization, and evaluation of the co-amorphous systems of dasatinib to improve its pharmaceutical attributes

R. B. Chavan, S. Ray, P. Kundu, S. A. Dupakuntla, S. Giri, P. Sivasankaran, G. Kuppusamy, S. K. Jain and R. Bokalial, CrystEngComm, 2025, Advance Article , DOI: 10.1039/D5CE00064E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements